The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,218,481 | -6,676,281 |
| Stock-based compensation | 18,452 | 84,208 |
| Common stock issued for license agreement | 0 | - |
| Depreciation | 697 | 2,201 |
| Gain on disposal of fixed assets | 0 | 0 |
| Prepaid expenses and other current assets | -401,661 | 1,060,681 |
| Deferred offering costs | 43,700 | - |
| Accounts payable and accrued expenses | 667,201 | -934,614 |
| Net cash used in operating activities | -2,174,170 | -8,585,167 |
| Payments of deferred offering costs | 0 | 0 |
| Payments on notes payable | 90,974 | 175,788 |
| Proceeds from exercise of warrants | 844 | 2,783 |
| Payments to stockholders for stock split rounding | 1,486 | 557 |
| Proceeds from subscription receivable | 0 | 882,539 |
| Proceeds from sale of common stock and warrants, net | 0 | 13,544,685 |
| Net cash provided by financing activities | -91,616 | 14,253,662 |
| Net change in cash and cash equivalents | -2,265,786 | 5,668,495 |
| Cash and cash equivalents at beginning of period | 6,461,378 | - |
| Cash and cash equivalents at end of period | 9,864,087 | - |
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)